LONG ISLAND CITY, N.Y., Oct. 2, 2024 /PRNewswire/ -- Ambetter from Fidelis, a product offered by a Centene Corporation (NYSE: CNC) company, which provides insurance to under-insured and uninsured populations through NY State of Health, the official Health Plan Marketplace, will offer a variety of affordable health insurance plans to New Yorkers in 56 counties for plan year 2025. Open enrollment for New York Qualified Health Plans runs from Nov. 16, 2024, through Jan. 31, 2025. Enroll by Dec. 15, 2024, for coverage starting Jan. 1, 2025.
"Fidelis Care was among the first health insurers to support the health and wellness of communities with Qualified Health Plans through New York State of Health," said Fidelis Care Chief Operating Officer Andi Gillentine. "With expanded 2025 benefits that help pregnant individuals and people with diabetes, we are confident that our recently renamed Ambetter from Fidelis Care plans will continue to offer quality, affordable health coverage to New Yorkers."
Ambetter from Fidelis Care offers its members access to quality care, convenient services and valuable rewards. The 2025 benefits and offerings include:
Below is a full list of counties in which Ambetter from Fidelis Care will be offered:
New York residents interested in learning more about Ambetter from Fidelis Care or enrolling in a health plan during the open enrollment period may visit fideliscare.org.
About Fidelis Care
Fidelis Care is a mission-driven health plan offering quality, affordable coverage for children and adults of all ages and at all stages of life. With more than 2.4 million members statewide, Fidelis Care believes that all New Yorkers should have access to affordable, quality health insurance. Follow us on LinkedIn at linkedin.com/company/fidelis-care, on Twitter at @fideliscare, Instagram at @fideliscare, and on Facebook at facebook.com/fideliscare. For more information, call Fidelis Care at 1-888-FIDELIS (1-888-343-3547) or visit fideliscare.org. Ambetter Health is a health insurance offering that is available on the Health Insurance Marketplace, or exchange, established by the Affordable Care Act. This is a solicitation for insurance.
Last Trade: | US$63.52 |
Daily Change: | 1.74 2.82 |
Daily Volume: | 5,286,820 |
Market Cap: | US$33.410B |
October 30, 2024 October 25, 2024 September 11, 2024 August 29, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB